Clinical Trial Update: Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Participants and Participants With Dry Eye [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety, tolerability, and systemic pharmacokinetics of AGN-232411 in healthy participants and individuals with dry eye disease; the tria…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Disease

Drugs mentioned

• AGN-232411

Snippet

Sponsor: Allergan | Conditions: Healthy Volunteers, Dry Eye Syndromes | Phase 1 | Status: COMPLETED